Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome

• Status: Recruiting
• Trial end date: 2021-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

Treatment of obesity related to Polycystic Ovary Syndrome with topiramate or placebo to assess improvement of clinical and laboratory parameters after 6 months of follow-up

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital de Clinicas de Porto Alegre
• Treatments: Topiramate

Criteria

Inclusion Criteria:

• age between 18 and 40 years

• diagnostic criteria for PCOS

• overweight with a BMI ≥ 27 kg / m² associated with at least one comorbidity (hypertension, type 2 diabetes mellitus, dyslipidemia) or obesity with a BMI between 30 and 45 kg / m² with or without comorbidities

Exclusion Criteria:

• severe systemic arterial hypertension (≥180 / 100 mmHg)

• pregnant or lactating women

• diabetics using sulfonylurea or insulin

• any known allergy or intolerance to topiramate medication